Axsome Therapeutics
AXSM
36 hedge funds and large institutions have $10.4M invested in Axsome Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 10 closing their positions.
1,800% more call options, than puts
Call options by funds: $38K | Put options by funds: $2K
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
3% more funds holding
Funds holding: 35 → 36 (+1)
6.26% less ownership
Funds ownership: 22.88% → 16.61% (-6.3%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
68% less capital invested
Capital invested by funds: $32.6M → $10.4M (-$22.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$579K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$243K |
| 3 |
RA
Royce & Associates
New York
|
+$225K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$178K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.82M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.69M |
| 3 |
Millennium Management
New York
|
-$705K |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$704K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$670K |
AXSM Hedge Fund Activity: Q1 2018 in Review
36 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2018, worth a combined $10.4M — down 68% from $32.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AXSM positions and 10 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $579K. The largest seller was JP Morgan Chase, cutting an estimated $3.82M.
- 36 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2018, up from 35 in Q4 2017.
- Funds reported $10.4M of Axsome Therapeutics stock for Q1 2018, down 68% quarter-over-quarter.
- 11 funds opened new Axsome Therapeutics positions in Q1 2018 and 10 closed out, a net change of +1 holder.
- The largest Axsome Therapeutics buyer in Q1 2018 was Sio Capital Management, an estimated $579K added.
- The largest Axsome Therapeutics seller in Q1 2018 was JP Morgan Chase, an estimated $3.82M sold.
Based on aggregated 13F filings for Q1 2018.